FindTrial
Sign In

AP01

COMBINATION_PRODUCT2 trials

Sponsors

Avalyn Pharma Inc.

Conditions

Hypersensitivity PneumonitisIdiopathic Pulmonary Fibrosis (IPF)Interstitial Lung DiseaseInterstitial Lung Disease Due to Connective Tissue Disease (Disorder)Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified ElsewhereInterstitial Lung Disease With Systemic SclerosisInterstitial Lung Disease in Patients With Rheumatoid ArthritisProgressive Pulmonary Fibrosis

Phase 2

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Active, not recruitingNCT06329401
Avalyn Pharma Inc.Hypersensitivity Pneumonitis, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder) +7
Start: 2024-04-03End: 2027-06-01Target: 375Updated: 2026-07-02
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
RecruitingNCT06951217
Avalyn Pharma Inc.Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
Start: 2025-04-17End: 2031-12-31Target: 340Updated: 2026-08-28

Related Papers

Design of the MIST study: a double-blind, randomised, placebo-controlled phase 2b trial of pirfenidone solution for inhalation in patients with progressive pulmonary fibrosis.
2025-12-25